ffect of dupilumab on mucus burden in patients with moderate-to-severe asthma:the VESTIGE trial
| Title: | ffect of dupilumab on mucus burden in patients with moderate-to-severe asthma:the VESTIGE trial |
|---|---|
| Authors: | Porsbjerg, Celeste; Dunican, Eleanor M.; Lugogo, Njira L.; Castro, Mario; Papi, Alberto; Backer, Vibeke; Brightling, Christopher E.; Bourdin, Arnaud; Virchow, J. Christian; Zhang, Mei; Soler, Xavier; Rowe, Paul J.; Deniz, Yamo; de Prado Gómez, Lucía; Sacks, Harry J.; Jacob-Nara, Juby A. |
| Source: | Porsbjerg , C , Dunican , E M , Lugogo , N L , Castro , M , Papi , A , Backer , V , Brightling , C E , Bourdin , A , Virchow , J C , Zhang , M , Soler , X , Rowe , P J , Deniz , Y , de Prado Gómez , L , Sacks , H J & Jacob-Nara , J A 2026 , ' ffect of dupilumab on mucus burden in patients with moderate-to-severe asthma : the VESTIGE trial ' , American Journal of Respiratory and Critical Care .... |
| Publication Year: | 2026 |
| Collection: | University of Copenhagen: Research / Forskning ved Københavns Universitet |
| Description: | RATIONALE: Chronic mucus hypersecretion contributes to airway obstruction in asthma. OBJECTIVES: Assess dupilumab efficacy by baseline mucus plug score. METHODS: In VESTIGE (NCT04400318), adults with moderate-to-severe asthma, baseline blood eosinophils ≥300 cells/μL, and fractional exhaled nitric oxide (FeNO) ≥25 ppb received dupilumab 300 mg (n=72) or placebo (n=37) every 2 weeks for 24 weeks. Post hoc analyses included mucus plug score change from baseline, and patient proportion achieving FeNO |
| Document Type: | article in journal/newspaper |
| File Description: | application/pdf |
| Language: | English |
| DOI: | 10.1164/rccm.202410-1894OC |
| Availability: | https://researchprofiles.ku.dk/da/publications/c8bb95d2-7e1c-42d6-b6f6-bd273946dfca; https://doi.org/10.1164/rccm.202410-1894OC; https://curis.ku.dk/ws/files/538011948/rccm.202410-1894oc.pdf |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.3754A88F |
| Database: | BASE |